Main menu


Australia is developing a new vaccine that kills Corona virus particles in the lungs

A team of international scientists from the Menzies Health Institute at Griffith University in Australia has developed an anti-virus vaccine, and scientists said that the new treatment can kill 99.9% of the Corona virus particles in the lungs, as it works through a new medical technique called "gene silencing" that detects corona virus particles Then attacks her, according to what was published by the British newspaper "Daily Mail".

Professor Nigel Macmillan, associate researcher at the Menzies Institute of Health at Griffith University, said that treatment prevents the virus from reproducing and may put an end to deaths associated with the Corona virus around the world, adding, "We can specifically destroy the virus that grows in someone's lungs."

He added that the new treatment works using a medical technique called "gene silencing" that was first discovered in Australia during the 1990s. Gene silencing uses RNA - building blocks of the body, similar to DNA - to attack respiratory diseases.

"This is a technique that works with small pieces of RNA that can specifically bind to the genome of the virus," Professor Macmillan explained.

This association causes the genome to not function anymore, and in fact causes cells to destroy it.

Although there are other antiviral treatments like Zanamivir and Remdesivir that alleviate symptoms and allow coronavirus patients to recover faster, this is the first treatment to stop the virus directly.

The drug must be delivered into the bloodstream by injection of a substance called "nanoparticles." "These nanoparticles go to the lungs and integrate into the cells that transport the RNA," said Professor Macmillan.

The RNA looks for the virus and destroys its genome, so the virus is no longer able to reproduce.

Scientists have been working on the treatment since April of last year, when orders were issued to close Australia nationwide for a period of six weeks, and the Griffith University treatment is now set to enter the next phase of clinical trials and is expected to be available by 2023.